Senior Director, Medical Device Pathology and Neuropathology StageBio Frederick, Maryland, United States
This presentation will focus on key considerations for designing a histopathology safety assessment to evaluate potential neurotoxicity of novel therapeutics including vector-based and cell-based therapies. Specialized neuropathology evaluations will be reviewed along with implications of direct delivery to the central nervous system. Focused discussion will review changes associated with stem cell therapies, CAR T-cell therapies, and adeno-associated viral vectors.
